Discover
MDGL
Madrigal Pharmaceuticals, Inc.
497.65
1 x 494.58
1 x 499.27
bid
ask
+
1.20
0.24%
11:26 AM
timesize
| Ytd | -14.54% | |
| 1y | 14.07% |
491.25
day range
501.16
393.61
52 week range
615.00
| Open | 492.61 | Prev Close | 496.45 | Low | 491.25 | High | 501.16 | Mkt Cap | 11.51B |
| Vol | 47.26K | Avg Vol | 292.63K | EPS | -12.85 | P/E | N/A | Forward P/E | 51.58 |
| Beta | -1.04 | Short Ratio | 10.22 | Inst. Own | 104.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 521.14 | 200-d Avg | 510.06 | 1yr Est | 682.11 |
| Income Statement | |||
| Total Revenue | 364.25M | ||
| Revenues (USD) | 364.25M | ||
| Cost of Revenue | 40.01M | ||
| Gross Profit | 324.25M | ||
| Operating Expenses | 380.55M | ||
| Research and Development Expense | 91.18M | ||
| Selling, General and Administrative Expense | 289.38M | ||
| Operating Income | -56.31M | ||
| Interest Expense | 7.94M | ||
| Net Income | -57.94M | ||
| Net Income Common Stock | -57.94M | ||
| Net Income Common Stock (USD) | -57.94M | ||
| Consolidated Income | -57.94M | ||
| Earnings per Basic Share | -1.99 | ||
| Earnings per Basic Share (USD) | -1.99 | ||
| Earnings per Diluted Share | -1.99 | ||
| Earning Before Interest & Taxes (EBIT) | -50.00M | ||
| Earning Before Interest & Taxes (USD) | -50.00M | ||
| Weighted Average Shares | 29.15M | ||
| Weighted Average Shares Diluted | 29.15M | ||
| Balance Sheet | |||
| Cash and Equivalents | 292.88M | ||
| Cash and Equivalents (USD) | 292.88M | ||
| Investments | 546.03M | ||
| Investments Current | 546.03M | ||
| Trade and Non-Trade Receivables | 192.31M | ||
| Current Assets | 1.20B | ||
| Property, Plant & Equipment Net | 17.17M | ||
| Total Assets | 1.24B | ||
| Debt Current | 1.03M | ||
| Total Debt | 347.75M | ||
| Current Liabilities | 374.20M | ||
| Debt Non-Current | 346.72M | ||
| Total Liabilities | 720.92M | ||
| Accumulated Retained Earnings (Deficit) | -2.24B | ||
| Accumulated Other Comprehensive Income | 808.00K | ||
| Shareholders Equity | 523.72M | ||
| Shareholders Equity (USD) | 523.72M | ||
| Assets Non-Current | 45.47M | ||
| Total Debt (USD) | 347.75M | ||
| Goodwill and Intangible Assets | 7.19M | ||
| Inventory | 99.39M | ||
| Liabilities Non-Current | 346.72M | ||
| Trade and Non-Trade Payables | 34.51M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.03M | ||
| Net Cash Flow from Financing | 3.11M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 60.69M | ||
| Capital Expenditure | -4.25M | ||
| Issuance (Purchase) of Equity Shares | 3.11M | ||
| Net Cash Flow from Investing | 34.20M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 38.45M | ||
| Net Cash Flow from Operations | 23.33M | ||
| Effect of Exchange Rate Changes on Cash | 57.00K | ||
| Share Based Compensation | 35.37M | ||